RESUMEN
PURPOSE: Hemorrhagic stroke (HS) is a devastating complication during extracorporeal membrane oxygenation (ECMO) but markers of risk stratification during COVID-19 are unknown. Lactate dehydrogenase (LDH) is a readily available biomarker of cell injury and permeability. We sought to determine whether an elevated LDH before ECMO placement is related to the occurrence of HS during ECMO for COVID-19. METHODS: Adult patients with COVID-19 requiring ECMO between March 2020 and February 2022 were included. LDH values prior to ECMO placement were captured. Patients were categorized into high (> 750 U/L) or low (≤ 750 U/L) LDH groups. Multivariable regression modeling was used to determine the association between LDH and HS during ECMO. RESULTS: There were 520 patients that underwent ECMO placement in 17 centers and 384 had an available LDH. Of whom, 122 (32%) had a high LDH. The overall incidence of HS was 10.9%, and patients with high LDH had a higher incidence of HS than those with low LDH level (17% vs 8%, p = 0.007). At 100 days, the probability of a HS was 40% in the high LDH group and 23% in those with a low LDH, p = 0.002. After adjustment for clinical covariates, high LDH remained associated with subsequent HS (aHR: 2.64, 95% CI 1.39-4.92). Findings were similar when restricting to patients supported by venovenous ECMO only. CONCLUSION: Elevated LDH prior to ECMO cannulation is associated with a higher incidence of HS during device support. LDH can risk stratify cases for impending cerebral bleeding during ECMO.
Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Accidente Cerebrovascular Hemorrágico , Adulto , Humanos , COVID-19/terapia , Oxigenación por Membrana Extracorpórea/efectos adversos , Estudios Retrospectivos , Lactato DeshidrogenasasRESUMEN
Systemic inflammatory response and hemodilution are prominent factors associated with cardiopulmonary bypass and result in increased morbidity and mortality in children. Miniaturized systems have evolved to decrease such effects and restrict use of blood products, especially in the neonatal population. We have developed a table mounted cardiopulmonary bypass system that allows closer proximity of the system to the patient with consequent decrease in priming volumes, hemodilution, and its associated effects, and contributes to development into an ideally bloodless surgical approach.